President Donald Trump signed an executive order on Thursday directing the attorney general to finalize the move of cannabis from Schedule I to Schedule III under the Controlled Substances Act - a shift that stops well short of legalization but carries real downstream effects for tax law, medical research, and industry regulation. The response from Capitol Hill was, by Washington standards, striking: members of both parties called it a meaningful step. Then, almost in the same breath, they outlined everything else they still want done.
What Rescheduling Actually Changes - and What It Doesn't
The distinction between Schedule I and Schedule III is not symbolic. Under the CSA, Schedule I substances are classified as having no accepted medical use and a high potential for abuse - a designation that has long prevented cannabis businesses from deducting ordinary operating expenses on their federal taxes under a provision known as Section 280E. Moving to Schedule III removes that penalty, which for many cannabis operators has meant effective tax rates that bear no relationship to actual profitability. It also loosens certain research restrictions that have made clinical study of cannabis frustratingly difficult for decades.
Here's the catch, though: Schedule III status does not legalize cannabis under federal law. Production and distribution for non-medical purposes remain federal crimes. That matters enormously for the financial infrastructure of the cannabis industry. State-licensed dispensaries and cultivators - operating legally under their own state frameworks - still cannot access standard banking services without exposing financial institutions to federal liability. The result is an industry that runs largely on cash, a situation that, as Sen. Jeff Merkley (D-OR) bluntly noted, "encourages all sorts of criminal activities, including robberies of cannabis businesses operating in all cash, false accounting, money laundering, and organized crime."
Bipartisan Praise, Divergent Endgames
The breadth of support for Thursday's order was genuine - and genuinely unusual. Rep. Dave Joyce (R-OH) and Rep. Brian Mast (R-FL), co-chairs of the Congressional Cannabis Caucus, both issued substantive statements of support. Mast, a combat veteran and Army veteran-turned-congressman, framed the order explicitly around veterans' access to treatment, citing cannabis's potential role in managing chronic pain and the psychological wounds that don't show up on an X-ray. Joyce pointed to the concrete barrier that Schedule I status has posed for evidence-based medicine, particularly for seniors and veterans seeking alternatives to conventional pharmaceuticals.
But among Democratic lawmakers, the praise came bundled with a clear legislative agenda. Senate Minority Leader Chuck Schumer called the order "a step in the right direction" while naming two specific bills he intends to push: the SAFER Banking Act, which would extend federal protections to banks servicing state-licensed cannabis businesses, and the Cannabis Administration and Opportunity Act (CAOA), which would end federal prohibition altogether. Sen. Ron Wyden (D-OR) was less diplomatic - he called the order "just a half step" and made plain that legalization, not rescheduling, remains his benchmark. House Minority Leader Hakeem Jeffries connected the issue to mass incarceration and the broader failure of drug war-era sentencing policy, tying cannabis reform to the First Step Act as evidence of what bipartisan criminal justice work can actually produce.
The Banking Problem Isn't Going Away
The SAFER Banking Act has been introduced in multiple congressional sessions. It has passed the House more than once. It has not passed the Senate. The bill's logic is straightforward: if states have chosen to legalize cannabis, the businesses operating legally within those frameworks should not be forced to function without access to checking accounts, payroll services, or credit. The all-cash model isn't just operationally awkward - it creates genuine public safety risks and makes it harder for regulators to track financial flows in an industry that many states are trying to tax and monitor closely.
Merkley, who has sponsored previous iterations of the banking bill, noted that even after rescheduling, cannabis businesses remain in violation of federal criminal law for non-medical purposes. That legal reality is precisely why banks have been reluctant to serve them. Schedule III status won't fix that. To put it plainly, rescheduling resolves the tax problem. It does not resolve the banking problem. And those are different problems with different legislative solutions.
Criminal Justice Reform Still Waits in the Queue
Rep. Lucy McBath (D-GA) identified the piece of the puzzle that tends to get eclipsed in policy debates dominated by industry and research considerations: the tens of thousands of people currently incarcerated for cannabis-related offenses. Her statement was pointed - "we cannot, in good faith, advance an industry while denying impacted individuals a clear path home." She pointed to the Clean Slate Act, legislation she leads, as the appropriate vehicle for addressing criminal records tied to marijuana convictions.
That argument surfaces a genuine tension in the current reform moment. The executive order benefits cannabis businesses and expands medical research capacity. It does not expunge records. It does not release anyone from incarceration. Communities most harmed by decades of enforcement-heavy drug policy - disproportionately Black and Latino communities, as Wyden noted explicitly - are not the primary beneficiaries of a tax reclassification. That asymmetry is not a reason to oppose rescheduling; it's a reason the legislative work that follows it matters as much as the order itself.
The order is real progress. What it reveals, more than anything, is how much further the map extends.
